全文获取类型
收费全文 | 1735篇 |
免费 | 102篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 24篇 |
儿科学 | 61篇 |
妇产科学 | 89篇 |
基础医学 | 171篇 |
口腔科学 | 50篇 |
临床医学 | 127篇 |
内科学 | 412篇 |
皮肤病学 | 11篇 |
神经病学 | 91篇 |
特种医学 | 62篇 |
外科学 | 341篇 |
综合类 | 27篇 |
预防医学 | 89篇 |
眼科学 | 15篇 |
药学 | 65篇 |
中国医学 | 6篇 |
肿瘤学 | 201篇 |
出版年
2023年 | 18篇 |
2022年 | 9篇 |
2021年 | 42篇 |
2020年 | 20篇 |
2019年 | 37篇 |
2018年 | 54篇 |
2017年 | 50篇 |
2016年 | 31篇 |
2015年 | 33篇 |
2014年 | 58篇 |
2013年 | 75篇 |
2012年 | 127篇 |
2011年 | 124篇 |
2010年 | 66篇 |
2009年 | 63篇 |
2008年 | 109篇 |
2007年 | 140篇 |
2006年 | 101篇 |
2005年 | 97篇 |
2004年 | 109篇 |
2003年 | 123篇 |
2002年 | 99篇 |
2001年 | 20篇 |
2000年 | 17篇 |
1999年 | 17篇 |
1998年 | 12篇 |
1997年 | 17篇 |
1996年 | 12篇 |
1995年 | 14篇 |
1994年 | 7篇 |
1993年 | 4篇 |
1992年 | 5篇 |
1991年 | 7篇 |
1990年 | 9篇 |
1989年 | 11篇 |
1988年 | 5篇 |
1987年 | 5篇 |
1986年 | 4篇 |
1984年 | 7篇 |
1982年 | 5篇 |
1981年 | 7篇 |
1979年 | 6篇 |
1978年 | 6篇 |
1977年 | 3篇 |
1976年 | 3篇 |
1975年 | 4篇 |
1971年 | 3篇 |
1969年 | 3篇 |
1966年 | 6篇 |
1964年 | 3篇 |
排序方式: 共有1842条查询结果,搜索用时 15 毫秒
1.
Laurien J. Zeverijn Eleonora J. Looze Subotheni Thavaneswaran J. Maxime van Berge Henegouwen Robert J. Simes Louisa R. Hoes Katrin M. Sjoquist Hanneke van der Wijngaart Lucille Sebastian Birgit S. Geurts Chee K. Lee Gijsbrecht F. de Wit David Espinoza Paul Roepman Frank P. Lin Anne M. L. Jansen Wendy W. J. de Leng Vincent van der Noort Lindsay V. M. Leek Filip Y. F. L. de Vos Carla M. L. van Herpen Hans Gelderblom Henk M. W. Verheul David M. Thomas Emile E. Voest 《International journal of cancer. Journal international du cancer》2023,153(7):1413-1422
The Dutch Drug Rediscovery Protocol (DRUP) and the Australian Cancer Molecular Screening and Therapeutic (MoST) Program are similar nonrandomized, multidrug, pan-cancer trial platforms that aim to identify signals of clinical activity of molecularly matched targeted therapies or immunotherapies outside their approved indications. Here, we report results for advanced or metastatic cancer patients with tumors harboring cyclin D-CDK4/6 pathway alterations treated with CDK4/6 inhibitors palbociclib or ribociclib. We included adult patients that had therapy-refractory solid malignancies with the following alterations: amplifications of CDK4, CDK6, CCND1, CCND2 or CCND3, or complete loss of CDKN2A or SMARCA4. Within MoST, all patients were treated with palbociclib, whereas in DRUP, palbociclib and ribociclib were assigned to different cohorts (defined by tumor type and alteration). The primary endpoint for this combined analysis was clinical benefit, defined as confirmed objective response or stable disease ≥16 weeks. We treated 139 patients with a broad variety of tumor types; 116 with palbociclib and 23 with ribociclib. In 112 evaluable patients, the objective response rate was 0% and clinical benefit rate at 16 weeks was 15%. Median progression-free survival was 4 months (95% CI: 3-5 months), and median overall survival 5 months (95% CI: 4-6 months). In conclusion, only limited clinical activity of palbociclib and ribociclib monotherapy in patients with pretreated cancers harboring cyclin D-CDK4/6 pathway alterations was observed. Our findings indicate that monotherapy use of palbociclib or ribociclib is not recommended and that merging data of two similar precision oncology trials is feasible. 相似文献
2.
3.
Cutaneous histiocytoses constitute a heterogeneous group of diseases characterised by the cutaneous accumulation of cells with the cytological and phenotypic features of macrophages or dendritic cells. The clinical spectrum ranges from self-resolving, skin-limited conditions to severe, multiorgan disease with a high morbidity rate. Until recently, cutaneous histiocytoses were classified according to the immunophenotype of the pathological cells, with differentiation between Langerhans cell histiocytosis (LCH) [CD1a+, CD207 (langerin)+] and non-Langerhans cell histiocytosis (CD68+, CD163+, CD1a?, CD207?). Over the last 12 years, a number of new pathophysiological findings (in particular, molecular pathology results) regarding histiocytoses have contributed to a new classification based on molecular alterations, as well as on clinical and imaging characteristics and the phenotype. The most frequent entities in children are juvenile xanthogranuloma and LCH. 相似文献
4.
5.
Emile Gogineni Zaker Rana Michael Wotman Jessie Karten Adam Riegel Mihaela Marrero Luis Maduro Dev Kamdar Douglas Frank Doru Paul Nagashree Seetharamu Maged Ghaly 《Journal of Geriatric Oncology》2021,12(1):122-127
PurposeManagement of head and neck cancers (HNC) in older adults is a common but challenging clinical scenario. We assess the impact of Stereotactic Body Radiation Therapy (SBRT) on survival utilizing the Geriatric-8 (G8) questionnaire.Materials and methods171 HNC patients, deemed medically unfit for definitive treatment, were treated with SBRT ± systemic therapy. G8 questionnaires were collected at baseline, at 4–6 weeks, and at 2–3 months post-treatment. Patients were stratified according to their baseline G8 score: <11 as ‘vulnerable’, 11–14 as ‘intermediate’, and >14 as ‘fit’. Overall survival (OS) was assessed through univariate Kaplan Meier analysis. Repeated measures ANOVA was used to determine if baseline characteristics affected G8 score changes.ResultsMedian follow-up was seventeen months. 60% of patients presented with recurrent HNC, 30% with untreated HNC primaries, and 10% with metastatic non-HNC primaries. Median age was 75 years. Median Charlson Comorbidity Index score was 2. 51% of patients were ‘vulnerable’, 37% were ‘intermediate’, and 12% were ‘fit' at baseline, with median survival of 13.2, 24.3, and 41.0 months, respectively (p = .004). Patients who saw a decrease in their follow-up G8 score (n = 69) had significantly lower survival than patients who had stable or increased follow-up G8 scores (n = 102), with median survival of 8.6 vs 36.0 months (p < .001).ConclusionThe G8 questionnaire may be a useful tool in upfront treatment decision-making to predict prognosis and prevent older patients from receiving inappropriate anti-cancer treatment. Decline in follow-up G8 scores may also predict worse survival and aid in goals of care following treatment. 相似文献
6.
7.
8.
Despoina Koulenti Andrew Song Aaron Ellingboe Mohd Hafiz Abdul-Aziz Patrick Harris Emile Gavey Jeffrey Lipman 《International journal of antimicrobial agents》2019,53(3):211-224
The spread of multidrug-resistant bacteria is an ever-growing concern, particularly among Gram-negative bacteria because of their intrinsic resistance and how quickly they acquire and spread new resistance mechanisms. Treating infections caused by Gram-negative bacteria is a challenge for medical practitioners and increases patient mortality and cost of care globally. This vulnerability, along with strategies to tackle antimicrobial resistance development, prompts the development of new antibiotic agents and exploration of alternative treatment options. This article summarises the new antibiotics that have recently been approved for Gram-negative bacterial infections, looks down the pipeline at promising agents currently in phase I, II, or III clinical trials, and introduces new alternative avenues that show potential in combating multidrug-resistant Gram-negative bacteria. 相似文献
9.
Early labor force exit subsequent to permanently impairing occupational injury or illness among workers 50‐64 years of age 下载免费PDF全文
Kenneth A. Scott MPH PhD Qing Liao MSc Gwenith G. Fisher PhD Lorann Stallones MPH PhD Carolyn DiGuiseppi MD MPH PhD Emile Tompa PhD 《American journal of industrial medicine》2018,61(4):317-325
Background
Severity of workplace injury tends to increase with age. Whether older workers who experience a workplace injury or illness exit the labor force sooner than comparable peers is not established.Methods
A case‐cohort study design and complementary log‐log model were used to identify factors associated with average time to early substantial labor force exit among workers’ compensation claimants 50‐64 years of age with permanent impairment from an occupational injury or illness. Analysis was based on Ontario's workers’ compensation claimant data from 1998 to 2006 linked with Canadian tax files.Results
Workers with permanent impairment left the labor force earlier, on average, than peers without claims. Early retirement was associated with older age in the injury/illness year, greater impairment, lower pre‐claim income, physically demanding jobs, and soft‐tissue injuries.Conclusions
Policies aiming to extend older adults’ working lives should account for the potentially disparate impacts on older workers of occupational injury and illness.10.
The purpose of this study was to evaluate the frictional resistance of various bracket/archwire combinations. The friction testing apparatus allowed dynamic and progressive bracket tipping and uprighting concurrent with linear bracket traction which experimentally approximated canine retraction with sliding mechanics. Multiple ANOVA using general linear models procedure demonstrated significant effects (P < 0.05) for bracket type, archwire type, archwire size, and archwire shape, as well as pair-wise interactions for bracket type/archwire type, bracket type/archwire size, bracket type/archwire shape, archwire type/archwire size, archwire type/archwire shape, and archwire size/archwire shape. Duncan’s multiple range test (P < 0.05) revealed the general trends regarding frictional performance of brackets and archwires tested, while Least squares means table (P < 0.05) illustrated significant interactions of pair-wise factors that differed from the general trends. It was concluded that: (1) Ceramic brackets with and without metal slots had the greatest friction followed by metal brackets, active self-ligating brackets, variable self-ligating brackets, and passive self-ligating brackets. (2) Stainless steel and braided stainless archwires measured greater friction than nickel-titanium. (3) Smaller dimension wires had less friction than larger wires, and round wires had less friction than rectangular wires. In addition, consideration of specific bracket-archwire coupling appear to reduce the frictional resistance with sliding. 相似文献